Repare Therapeutics Inc.
RPTX
$1.36
$0.118.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.58% | 18.19% | -58.79% | -28.62% | -61.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.58% | 18.19% | -58.79% | -28.62% | -61.21% |
| Cost of Revenue | 1.05% | -94.95% | -91.43% | -88.22% | -88.66% |
| Gross Profit | 5.82% | 186.46% | 37.28% | 456.31% | 150.82% |
| SG&A Expenses | -10.89% | -2.77% | 1.15% | 4.59% | 3.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.99% | -1.57% | 2.90% | 7.55% | 10.37% |
| Operating Income | 20.72% | 12.17% | -1,502.87% | -259.97% | -487.11% |
| Income Before Tax | 19.32% | 10.39% | -546.89% | -452.98% | -642.29% |
| Income Tax Expenses | 115.35% | -70.12% | -169.49% | -166.04% | -161.95% |
| Earnings from Continuing Operations | 9.71% | 13.73% | -2,121.82% | -56.32% | -222.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.71% | 13.73% | -2,121.82% | -56.32% | -222.91% |
| EBIT | 20.72% | 12.17% | -1,502.87% | -259.97% | -487.11% |
| EBITDA | 21.05% | 12.46% | -1,176.37% | -287.24% | -541.33% |
| EPS Basic | 10.59% | 14.41% | -2,216.14% | -56.14% | -220.83% |
| Normalized Basic EPS | 21.43% | 12.72% | -541.11% | -453.40% | -634.77% |
| EPS Diluted | 10.07% | 13.95% | -921.20% | -39.74% | -184.07% |
| Normalized Diluted EPS | 20.89% | 12.11% | -656.97% | -309.26% | -477.24% |
| Average Basic Shares Outstanding | 0.75% | 0.63% | 0.52% | 0.42% | 0.41% |
| Average Diluted Shares Outstanding | 1.82% | 1.69% | 0.25% | 0.15% | -0.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |